152 related articles for article (PubMed ID: 22001978)
1. Buspirone improves the anti-cataleptic effect of levodopa in 6-hydroxydopamine-lesioned rats.
Mahmoudi J; Nayebi AM; Samini M; Reyhani-Rad S; Babapour V
Pharmacol Rep; 2011; 63(4):908-14. PubMed ID: 22001978
[TBL] [Abstract][Full Text] [Related]
2. Buspirone improves 6-hydroxydopamine-induced catalepsy through stimulation of nigral 5-HT(1A) receptors in rats.
Nayebi AM; Rad SR; Saberian M; Azimzadeh S; Samini M
Pharmacol Rep; 2010; 62(2):258-64. PubMed ID: 20508280
[TBL] [Abstract][Full Text] [Related]
3. 5-HT(1A) receptor activation improves anti-cataleptic effects of levodopa in 6-hydroxydopamine-lesioned rats.
Mahmoudi J; Mohajjel Nayebi A; Samini M; Reyhani-Rad S; Babapour V
Daru; 2011; 19(5):338-43. PubMed ID: 22615679
[TBL] [Abstract][Full Text] [Related]
4. Fluoxetine improves the effect of levodopa on 6-hydroxy dopamine-induced motor impairments in rats.
Mahmoudi J; Mohajjel Nayebi A; Reyhani-Rad S; Samini M
Adv Pharm Bull; 2012; 2(2):149-55. PubMed ID: 24312786
[TBL] [Abstract][Full Text] [Related]
5. Role of dopamine D3 and serotonin 5-HT 1A receptors in L: -DOPA-induced dyskinesias and effects of sarizotan in the 6-hydroxydopamine-lesioned rat model of Parkinson's disease.
Gerlach M; Bartoszyk GD; Riederer P; Dean O; van den Buuse M
J Neural Transm (Vienna); 2011 Dec; 118(12):1733-42. PubMed ID: 21253782
[TBL] [Abstract][Full Text] [Related]
6. The partial 5-HT(1A) agonist buspirone reduces the expression and development of l-DOPA-induced dyskinesia in rats and improves l-DOPA efficacy.
Eskow KL; Gupta V; Alam S; Park JY; Bishop C
Pharmacol Biochem Behav; 2007; 87(3):306-14. PubMed ID: 17553556
[TBL] [Abstract][Full Text] [Related]
7. Neuroinflammation and L-dopa-induced abnormal involuntary movements in 6-hydroxydopamine-lesioned rat model of Parkinson's disease are counteracted by combined administration of a 5-HT
Pinna A; Costa G; Serra M; Contu L; Morelli M
Neuropharmacology; 2021 Sep; 196():108693. PubMed ID: 34229013
[TBL] [Abstract][Full Text] [Related]
8. Synergistic effect of serotonin 1A and serotonin 1B/D receptor agonists in the treatment of L-DOPA-induced dyskinesia in 6-hydroxydopamine-lesioned rats.
Thomsen M; Stoica A; Christensen KV; Fryland T; Mikkelsen JD; Hansen JB
Exp Neurol; 2022 Dec; 358():114209. PubMed ID: 35988699
[TBL] [Abstract][Full Text] [Related]
9. Flibanserin attenuates L: -DOPA-sensitized contraversive circling in the unilaterally 6-hydroxydopamine-lesioned rat model of Parkinson's disease.
Gerlach M; Beck J; Riederer P; van den Buuse M
J Neural Transm (Vienna); 2011 Dec; 118(12):1727-32. PubMed ID: 21274579
[TBL] [Abstract][Full Text] [Related]
10. Buspirone requires the intact nigrostriatal pathway to reduce the activity of the subthalamic nucleus via 5-HT1A receptors.
Sagarduy A; Llorente J; Miguelez C; Morera-Herreras T; Ruiz-Ortega JA; Ugedo L
Exp Neurol; 2016 Mar; 277():35-45. PubMed ID: 26687972
[TBL] [Abstract][Full Text] [Related]
11. 6-Hydroxydopamine lesion and levodopa treatment modify the effect of buspirone in the substantia nigra pars reticulata.
Vegas-Suárez S; Pisanò CA; Requejo C; Bengoetxea H; Lafuente JV; Morari M; Miguelez C; Ugedo L
Br J Pharmacol; 2020 Sep; 177(17):3957-3974. PubMed ID: 32464686
[TBL] [Abstract][Full Text] [Related]
12. Activity of serotonin 5-HT(1A) receptor 'biased agonists' in rat models of Parkinson's disease and L-DOPA-induced dyskinesia.
Iderberg H; McCreary AC; Varney MA; Cenci MA; Newman-Tancredi A
Neuropharmacology; 2015 Jun; 93():52-67. PubMed ID: 25645393
[TBL] [Abstract][Full Text] [Related]
13. Serotonergic and dopaminergic mechanisms in graft-induced dyskinesia in a rat model of Parkinson's disease.
Shin E; Garcia J; Winkler C; Björklund A; Carta M
Neurobiol Dis; 2012 Sep; 47(3):393-406. PubMed ID: 22579773
[TBL] [Abstract][Full Text] [Related]
14. Combined 5-HT1A and 5-HT1B receptor agonists for the treatment of L-DOPA-induced dyskinesia.
Muñoz A; Li Q; Gardoni F; Marcello E; Qin C; Carlsson T; Kirik D; Di Luca M; Björklund A; Bezard E; Carta M
Brain; 2008 Dec; 131(Pt 12):3380-94. PubMed ID: 18952677
[TBL] [Abstract][Full Text] [Related]
15. NLX-112, a novel 5-HT1A receptor agonist for the treatment of L-DOPA-induced dyskinesia: Behavioral and neurochemical profile in rat.
Iderberg H; McCreary AC; Varney MA; Kleven MS; Koek W; Bardin L; Depoortère R; Cenci MA; Newman-Tancredi A
Exp Neurol; 2015 Sep; 271():335-50. PubMed ID: 26037043
[TBL] [Abstract][Full Text] [Related]
16. L-stepholidine reduced L-DOPA-induced dyskinesia in 6-OHDA-lesioned rat model of Parkinson's disease.
Mo J; Zhang H; Yu LP; Sun PH; Jin GZ; Zhen X
Neurobiol Aging; 2010 Jun; 31(6):926-36. PubMed ID: 18707801
[TBL] [Abstract][Full Text] [Related]
17. Chronic L-DOPA treatment attenuates behavioral and biochemical deficits induced by unilateral lactacystin administration into the rat substantia nigra.
Konieczny J; Czarnecka A; Lenda T; Kamińska K; Lorenc-Koci E
Behav Brain Res; 2014 Mar; 261():79-88. PubMed ID: 24361083
[TBL] [Abstract][Full Text] [Related]
18. The effect of chronic administration of buspirone on 6-hydroxydopamine-induced catalepsy in rats.
Sharifi H; Mohajjel Nayebia A; Farajnia S
Adv Pharm Bull; 2012; 2(1):127-31. PubMed ID: 24312782
[TBL] [Abstract][Full Text] [Related]
19. Dose-Dependent Effect of Flouxetine on 6-OHDA-Induced Catalepsy in Male Rats: A Possible Involvement of 5-HT1A Receptors.
Sharifi H; Mohajjel Nayebia A; Farajnia S
Adv Pharm Bull; 2013; 3(1):203-6. PubMed ID: 24312836
[TBL] [Abstract][Full Text] [Related]
20. The NK1 receptor antagonist N-acetyl-L-tryptophan reduces dyskinesia in a hemi-parkinsonian rodent model.
Thornton E; Hassall MM; Corrigan F; Vink R
Parkinsonism Relat Disord; 2014 May; 20(5):508-13. PubMed ID: 24637127
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
